Regulatory writing by therapeutic area
Every area has its own pressure points. Asthra drafts against them — neurology, oncology, rare disease, immunology — inside Microsoft Word, with citations and human review.
The core Asthra product supports Clinical Study Reports, Periodic Safety Update Reports, Clinical Evaluation Reports, and CMC Module 3 across every therapeutic area. These pages exist because the pressure around each document varies a lot by area: oncology DSURs differ from neurology CSRs in meaningful ways, and rare-disease regulatory strategy is nothing like immunology. Pick the area closest to your work — the product is the same, but the framing is specific.
Choose your therapeutic area
Or jump to the document type you care about most
Neurology
Long trials, CNS safety signals, patient-reported outcomes, and the regulatory nuance of placebo-controlled design. Asthra handles the mechanical drafting so clinical judgement stays with the writer.
Read more →Oncology
Rapid accrual, frequent DSURs, dose-optimisation pressure, and interim-analysis-heavy CSRs. Asthra drafts against ICH E3 with honest traceability to the underlying TFL.
Read more →Rare disease
Small N, single-arm studies, natural-history comparators, and post-marketing commitments. Asthra reuses historical evidence carefully and flags what has genuinely changed.
Read more →Immunology
Long-term safety follow-up, opportunistic-infection reporting, immunogenicity, and biologic CMC. Asthra synthesises across reporting periods with consistent voice and citations.
Read more →Not sure where to start?
Tell us the therapeutic area and document type you're working on. We will configure a demo against the exact setup you care about.
Request a demoLast updated: 16 April 2026